🔬 Backed by Real Science — Not Trends
The technology inside ApexCapilare isn't new. It's been studied, tested, and validated by the medical community for over two decades.
🏛️ FDA-Cleared Technology
Low-Level Light Therapy (LLLT) devices for hair loss are FDA-cleared under the 510(k) pathway for the treatment of androgenetic alopecia in both men and women. This is the same regulatory standard applied to medical devices sold in U.S. hospitals and clinics.
📄 Peer-Reviewed Clinical Evidence
✅ Landmark Study (2013) — Published in the American Journal of Clinical Dermatology (Avci et al.), found that LLLT significantly increased hair count and density in participants with androgenetic alopecia after consistent use.
✅ Double-Blind Trial (2013) — Published in Lasers in Surgery and Medicine (Lanzafame et al.), demonstrated a 35% increase in hair growth in subjects treated with red light therapy vs. placebo.
✅ Systematic Review (2014) — Comprehensive analysis confirmed LLLT's efficacy for androgenetic alopecia with minimal side effects.
💡 Why This Matters for You
Unlike trends that come and go, ApexCapilare is backed by decades of peer-reviewed research and regulatory approval. You're not betting on hype — you're investing in clinically-proven technology that works.
🎯 The Bottom Line: When you choose ApexCapilare, you're choosing science, not trends.
*Avci et al. (2013) — American Journal of Clinical Dermatology
doi.org/10.1007/s40257-013-0077-4
*Lanzafame et al. (2013) — Lasers in Surgery and Medicine
doi.org/10.1002/lsm.22120
*FDA 510(k) clearance — LLLT devices for alopecia
accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm